Abstract
The potent neuropeptide vasodilator, calcitonin gene-related peptide (CGRP), and the vasoactive peptide adrenomedullin (AM) are structurally related. Evidence from our laboratory has demonstrated that these peptides have potent microvascular actions of relevance to cardiovascular and inflammatory effects in health and disease. We wish to further investigate the actions of these peptides through studies in genetically modified mice. We have developed techniques to enable the quantitative analysis of CGRP and AM responses in the mouse microvasculature. A mouse isolated mesentery system was developed that measures changes in perfusion pressure used as an index of microvascular relaxation in the precontracted mesenteric microvascular bed. Bolus injections of CGRP and AM caused dose-dependent decreases in perfusion pressure that were proportional to vascular relaxation. An in vivo mouse skin assay was also used in which agents were injected intradermally into the dorsal skin. The effects of these agents was assessed by the extravascular accumulation of intravenously injected 125I-albumin for their ability to potentiate plasma extravasation induced by a mediator of increased microvascular permeability. CGRP and AM are not directly active in this assay, because it does not directly measure blood flow. However, the vasodilators acted in a potent and dose-dependent manner to significantly potentiate edema formation. The results demonstrate the potent activity of CGRP and the activity (although 100- to 300-fold less potent) of AM. Furthermore, the results demonstrate the increased potency of CGRP in the microvasculature when compared with the structurally distinct peptide VIP and PGE1.
Similar content being viewed by others
References
Amerini S., Mantelli L., and Ledda F. (1993) Nitric oxide is not involved in the effects induced by non-adrenergic non-cholinergic stimulation and calcitonin gene-related peptide in the rat mesenteric vascular bed. Neuropeptides 25, 51–55.
Asanuma Y., Sato T., Kato T., Nanjo H., Kurokawa T., Yasui O., et al. (2002) Continuous arterial infusion of prostaglandin E(1) via the superior mesenteric artery in the treatment of postoperative liver failure. Ther. Apher. 6, 89–92.
Berthiaume N., Hess F., Chen A., Regoli D., and D’Orleans-Juste P. (1997) Pharmacology of kinins in the arterial and venous mesenteric bed of normal and B2 knockout transgenic mice. Eur. J. Pharmacol. 333, 55–61.
Brain S. D., Poyner D. R., and Hill R. G. (2002) CGRP receptors: a headache to study, but will antagonists prove therapeutic in migraine? Trends Pharmacol. Sci. 23, 51–53.
Brain S. D. and Williams T. J. (1985) Inflammatory oedema induced by synergism between calcitonin gene-related peptide (CGRP) and mediators of increased vascular permeability. Br. J. Pharmacol. 86, 855–860.
Brain S. D. and Williams T. J. (1988) Substance P regulates the vasodilator activity of calcitonin gene- related peptide. Nature 335, 73–75.
Brain S. D., Williams T. J., Tippins J. R., Morris H. R., and MacIntyre I. (1985) Calcitonin gene-related peptide is a potent vasodilator. Nature 313, 54–56.
Chiba T., Yamaguchi A., Yamatani T., Nakamura A., Morishita T., Inui T., et al. (1989) Calcitonin gene-related peptide receptor antagonist human CGRP-(8–37). Am. J. Physiol 256, E331-E335.
Chu D. Q., Choy M., Foster P., Cao T., and Brain S. D. (2000) A comparative study of the ability of calcitonin gene-related peptide and adrenomedullin (13–52) to modulate microvascular but not thermal hyperalgesia responses. Br. J. Pharmacol. 130, 1589–1596.
Chu D. Q., Legon S., Smith D. M., Costa S. K., Cuttitta F., and Brain S. D. (2001) The calcitonin gene-related peptide (CGRP) antagonist CGRP(8–37) blocks vasodilatation in inflamed rat skin: involvement of adrenomedullin in addition to CGRP. Neurosci. Lett. 310, 169–172.
Doods H., Hallermayer G., Wu D., Entzeroth M., Rudolf K., Engel W., et al. (2000) Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br. J. Pharmacol. 129, 420–423.
Escott K. J. and Brain S. D. (1993) Effect of a calcitonin gene-related peptide antagonist (CGRP8–37) on skin vasodilatation and oedema induced by stimulation of the rat saphenous nerve. Br. J. Pharmacol. 110, 772–776.
Grant A. D., Gerard N. P., and Brain S. D. (2002) Evidence of a role for NK1 and CGRP receptors in mediating neurogenic vasodilatation in the mouse ear. Br. J. Pharmacol. 135, 356–362.
Kawasaki H., Takasaki K., Saito A., and Goto K. (1988) Calcitonin gene-related peptide acts as a novel vasodilator neurotransmitter in mesenteric resistance vessels of the rat. Nature 335, 164–167.
Kitamura K., Kangawa K., Kawamoto M., Ichiki Y., Nakamura S., Matsuo H., et al. (1993) Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem. Biophys. Res. Commun. 192, 553–560.
Lundberg J. M., Franco-Cereceda A., Hua X., Hokfelt T., and Fischer J. A. (1985) Co-existence of substance P and calcitonin gene-related peptide-like immunoreactivities in sensory nerves in relation to cardiovascular and bronchoconstrictor effects of capsaicin. Eur. J. Pharmacol. 108, 315–319.
Marutsuka K., Hatakeyama K., Sato Y., Yamashita A., Sumiyoshi A., and Asada Y. (2003) Immunohistological localization and possible functions of adrenomedullin. Hypertens. Res. 26 Suppl, S33-S40.
McLatchie L. M., Fraser N. J., Main M. J., Wise A., Brown J., Thompson N., et al. (1998) RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393, 333–339.
Nuki C., Kawasaki H., Kitamura K., Takenaga M., Kangawa K., Eto T., et al. (1993) Vasodilator effect of adrenomedullin and calcitonin gene-related peptide receptors in rat mesenteric vascular beds. Biochem. Biophys. Res. Commun. 196, 245–251.
Ottesen B. and Fahrenkrug J. (1981) Effect of vasoactive intestinal polypeptide (VIP) upon myometrial blood flow in non-pregnant rabbit. Acta Physiol Scand. 112, 195–201.
Sugo S., Minamino N., Shoji H., Kangawa K., Kitamura K., Eto T., et al. (1994) Production and secretion of adrenomedullin from vascular smooth muscle cells: augmented production by tumor necrosis factor-alpha. Biochem. Biophys. Res. Commun. 203, 719–726.
Williams T. J. (1982) Vasoactive intestinal polypeptide is more potent than prostaglandin E2 as a vasodilator and oedema potentiator in rabbit skin. Br. J. Pharmacol. 77, 505–509.
Williams T. J. and Peck M. J. (1977) Role of prostaglandin-mediated vasodilatation in inflammation. Nature 270, 530–532.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tam, C., Brain, S.D. The assessment of vasoactive properties of CGRP and adrenomedullin in the microvasculature. J Mol Neurosci 22, 117–124 (2004). https://doi.org/10.1385/JMN:22:1-2:117
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/JMN:22:1-2:117